Roquette Strategically Acquires IFF Pharma Solutions

Roquette, a plant-based ingredients and pharmaceutical excipients manufacturer, announced today an agreement to acquire IFF Pharma Solutions, an excipients for oral dosage solutions producer, to reinforce its position as a major partner to the pharmaceutical industry.

The merger of the two businesses will refocus the company on Health and Nutrition, broaden its pharmaceutical offerings, and boost Roquette’s growth significantly.

IFF, based in New York, USA, is a leading producer of excipients for oral dosage solutions with a global presence, $1B in revenue, and ~1,100 employees. It offers a wide range of quality products to major pharmaceutical, food, and nutraceutical companies worldwide.

Roquette’s acquisition of IFF Pharma Solutions is a game-changer. It strengthens its position in the promising excipients market, boosts its presence in the US, and greatly enhances its formulation capabilities and drug delivery R&D. This move positions Roquette as the preferred partner for innovative drug delivery solutions, meeting customer needs and enhancing patient care.

Roquette and IFF target to close the transaction in the first half of 2025. Closing remains subject to regulatory clearance and satisfaction of other customary closing conditions.

Company

Logo:

Roquette

1 rue de la Haute Loge
62136 Lestrem
France

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read